Health Canada has authorized an adapted vaccine from Novavax to prevent COVID-19 in people age 12 and older. Novavax's product — Nuvaxovid XBB.1.5 Omicron subvariant COVID-19 vaccine — uses a ...

Novavax's vaccine, reformulated to target the recently circulating JN.1 subvariant of Omicron, was authorized by Health Canada in September. People who have concerns or had a bad immunization ...

Novavax has inked another settlement for a past COVID-19 vaccine supply deal. | Novavax has inked another settlement for a ...

Under the agreement with J&J, Canada would purchase up to 38 million doses of Janssen’s Ad26.COV2.S vaccine candidate on a not-for-profit basis for emergency pandemic use.

Under terms of the deal, the company and the UKHSA agreed to settle the outstanding amount under dispute related to upfront ...

Health Canada said Thursday it has authorized Novavax's updated COVID-19 vaccine for those aged 12 years and up. The product, called Nuvaxovid, is a protein-based vaccine. Health Canada said the ...

Novavax’s vaccine, reformulated to target the recently circulating JN.1 subvariant of Omicron, was authorized by Health Canada in September. People who have concerns or had a bad immunization ...

Health Canada has authorized Novavax's updated COVID-19 vaccine that protects against currently circulating variants of the virus. The protein-based vaccine, called Nuvaxovid, has been ...

An updated version of Novavax’s COVID-19 vaccine has been approved by Canada’s health agency. According to a Thursday update on the government’s vaccine portal, Health Canada will replace ...

Health Canada authorized Novavax's updated COVID-19 vaccine that protects against currently circulating variants of the virus on Thursday. The protein-based vaccine, called Nuvaxovid, targets the JN.